EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Src tyrosine kinase to enhance radioiodide uptake in breast cancer

Vikki L Poole, Mohammed M Alshahrani, Selvambigai Manivannan, Iñigo Landa iD, Aditi Hariharan, Rebecca J Thompson, Merve Kocbiyik, Caitlin E M Thornton, Katie Brookes, Alice Fletcher, Kristien Boelaert, Martin L Read iD und 2 weitere

Endocrine-Related Cancer · 2025

DOI: 10.1530/erc-24-0312 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Vikki L Poole und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Metabolism & Systems Science (MSS) and Centre for Endocrinology, Diabetes and Metabolism (CEDAM), College of Medicine and Health, Unive…. Hauptthemen laut MEDLINE: Breast Neoplasms, src-Family Kinases, Iodine Radioisotopes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium iodide symporter (NIS) expression in breast cancer renders radioiodide (RAI) a promising treatment modality. However, insufficient functional NIS within the plasma membrane limits RAI uptake (RAIU). We aimed to elucidate NIS regulatory mechanisms that impede RAIU in breast cancer and identify molecular targets for stimulating RAI-avidity in breast tumours. Mechanistic interaction between pituitary tumor-transforming gene-binding factor (PBF/PTTG1IP) and NIS was investigated through NanoBiT, co-immunoprecipitation, immunofluorescent microscopy, subcellular localisation and RAIU assays utilising wild-type and CRISPR-Cas9 PBF knockout breast cancer cells. In breast cancer cells, NIS:PBF interaction resulted in diminished RAIU, reversible through reduced PBF phosphorylation by the Src inhibitor dasatinib. Src overexpression diminished RAIU in a PBF-dependent manner that was mediated by Src myristoylation by N-myristoyltransferase 1 (NMT1). NMT1 inhibition significantly enhanced RAIU via Src and PBF in breast and thyroid cancer cells. Bioinformatic analyses revealed clinical associations between high Src and NMT1 expression and increased tumour recurrence in RAI-treated thyroid cancers indicating RAI-resistance. In breast cancer, high PBF and Src expression was associated with the more aggressive tumours that are most likely to benefit from targeted RAI therapy. We describe a new NIS regulatory pathway in breast cancer cells via Src myristoylation and PBF phosphorylation and show that the same pathway exists in thyroid cells, the canonical setting for the exploitation of NIS function. These findings reveal that PBF interaction with NIS may be modulated by Src, which in turn is susceptible to NMT inhibition, and suggest that targeting NMT1 may represent an innovative approach for augmenting RAI-avidity in breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast Neoplasmssrc-Family KinasesIodine RadioisotopesHumansFemaleSymportersCell Line, TumorDasatinibSecurinSodium-Iodide Symporters

Stichwörter der Autor:innen

NISPBF/PTTG1IPSrc myristoylationbreast cancerradioiodide

Substanzen

src-Family KinasesIodine RadioisotopesSymportersDasatinibSecurinSodium-Iodide Symporterspituitary tumor-transforming protein 1, human

Autor:innen und Institutionen

  • Department of Metabolism & Systems Science (MSS) and Centre for Endocrinology, Diabetes and Metabolism (CEDAM), College of Medicine and Health, University of Birmingham, Birmingham, UK.
  • Institut Gustave Roussy, Inserm U981, Villejuif, France.
  • IHU-National PRecISion Medicine Center in Oncology, Villejuif, France.
  • Department of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.

ORCID-Profile: Iñigo Landa, Martin L Read, Christopher J McCabe, Vicki E Smith

Zitieren

APA

Poole, V. L., Alshahrani, M. M., Manivannan, S., Landa, I., Hariharan, A., Thompson, R. J., Kocbiyik, M., Thornton, C. E. M., Brookes, K., Fletcher, A., Boelaert, K., Read, M. L., McCabe, C. J., & Smith, V. E. (2025). Targeting Src tyrosine kinase to enhance radioiodide uptake in breast cancer. Endocrine-Related Cancer. https://doi.org/10.1530/erc-24-0312

Vancouver

Poole VL, Alshahrani MM, Manivannan S, Landa I, Hariharan A, Thompson RJ, et al. Targeting Src tyrosine kinase to enhance radioiodide uptake in breast cancer. Endocrine-Related Cancer. 2025. doi:10.1530/erc-24-0312

BibTeX
@article{Poole2025,
  author = {Poole, Vikki L and Alshahrani, Mohammed M and Manivannan, Selvambigai and Landa, Iñigo and Hariharan, Aditi and Thompson, Rebecca J and Kocbiyik, Merve and Thornton, Caitlin E M and Brookes, Katie and Fletcher, Alice and Boelaert, Kristien and Read, Martin L and McCabe, Christopher J and Smith, Vicki E},
  title = {Targeting Src tyrosine kinase to enhance radioiodide uptake in breast cancer},
  journal = {Endocrine-Related Cancer},
  year = {2025},
  doi = {10.1530/erc-24-0312}
}
Kostenlos starten →